Role of pre-existing incomplete intestinal metaplasia in gastric adenocarcinoma: A retrospective case series analysis.
Gastric adenocarcinoma
Minireview
OLGA/OLGIM staging
Precancerous lesions
Retrospective study
Subtypes of intestinal metaplasia
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
26 Apr 2023
26 Apr 2023
Historique:
received:
27
12
2022
revised:
19
01
2023
accepted:
29
03
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
Risk stratification for patients with gastric precancerous lesions for endoscopic surveillance remains controversial. To analysis of patients having developed gastric adenocarcinoma during the period of follow-up. We conducted a retrospective study on patients having undergone upper endoscopy prior to the development of gastric adenocarcinoma. The presence and stage of precancerous lesions as well as subtype of intestinal metaplasia at the baseline endoscopy got evaluated. Literature mini-review was performed. Out of 1681 subjects in the Biobank, gastric adenocarcinoma was detected in five cases in whom previous endoscopy data with biopsies either from the corpus or antral part were available. All of the patients had incomplete intestinal metaplasia during the baseline endoscopy; all three subjects in whom intestinal metaplasia subtyping was performed according to Filipe The presence of incomplete intestinal metaplasia, in particular, that of Type III is a better predictor for gastric adenocarcinoma development than OLGA/OLGIM staging system. Subtyping of intestinal metaplasia have an important role in the risk stratification for surveillance decisions.
Sections du résumé
BACKGROUND
BACKGROUND
Risk stratification for patients with gastric precancerous lesions for endoscopic surveillance remains controversial.
AIM
OBJECTIVE
To analysis of patients having developed gastric adenocarcinoma during the period of follow-up.
METHODS
METHODS
We conducted a retrospective study on patients having undergone upper endoscopy prior to the development of gastric adenocarcinoma. The presence and stage of precancerous lesions as well as subtype of intestinal metaplasia at the baseline endoscopy got evaluated. Literature mini-review was performed.
RESULTS
RESULTS
Out of 1681 subjects in the Biobank, gastric adenocarcinoma was detected in five cases in whom previous endoscopy data with biopsies either from the corpus or antral part were available. All of the patients had incomplete intestinal metaplasia during the baseline endoscopy; all three subjects in whom intestinal metaplasia subtyping was performed according to Filipe
CONCLUSION
CONCLUSIONS
The presence of incomplete intestinal metaplasia, in particular, that of Type III is a better predictor for gastric adenocarcinoma development than OLGA/OLGIM staging system. Subtyping of intestinal metaplasia have an important role in the risk stratification for surveillance decisions.
Identifiants
pubmed: 37214563
doi: 10.12998/wjcc.v11.i12.2708
pmc: PMC10198109
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2708-2715Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other co-authors contributed their efforts in this manuscript.
Références
Cancer Cell Int. 2021 Mar 17;21(1):173
pubmed: 33731114
Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):205-23
pubmed: 23809241
Dig Dis Sci. 2020 Jul;65(7):1899-1903
pubmed: 32356261
Gastric Cancer. 2018 Jul;21(4):579-587
pubmed: 29460004
Endoscopy. 2019 Apr;51(4):365-388
pubmed: 30841008
Virchows Arch. 2021 Oct;479(4):679-686
pubmed: 33990867
Gastroenterology. 2020 Feb;158(3):745-750
pubmed: 31887261
Gastroenterology. 2008 Apr;134(4):945-52
pubmed: 18395075
Clin Transl Gastroenterol. 2020 Dec;11(12):e00237
pubmed: 33512802
Gut. 2022 Aug 8;:
pubmed: 35944925
Acta Histochem Cytochem. 2021 Dec 24;54(6):185-194
pubmed: 35023881
Gastroenterology. 2021 Mar;160(4):1106-1117.e3
pubmed: 33220252
Am J Gastroenterol. 2018 Nov;113(11):1621-1628
pubmed: 30333540
Int J Cancer. 1994 May 1;57(3):324-9
pubmed: 8168991
Clin Transl Gastroenterol. 2021 Oct 1;12(10):e00402
pubmed: 34597278
J Gastroenterol Hepatol. 2016 May;31(5):953-8
pubmed: 26630310
Gut. 2022 May;71(5):854-863
pubmed: 33975867
Endoscopy. 2012 Jan;44(1):74-94
pubmed: 22198778